Locally Advanced Pancreatic Ductal Adenocarcinoma Clinical Trials

10 recruiting

Locally Advanced Pancreatic Ductal Adenocarcinoma Trials at a Glance

11 actively recruiting trials for locally advanced pancreatic ductal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Portland, Houston, and Irvine. Lead sponsors running locally advanced pancreatic ductal adenocarcinoma studies include OHSU Knight Cancer Institute, Jonsson Comprehensive Cancer Center, and Fox Chase Cancer Center.

Browse locally advanced pancreatic ductal adenocarcinoma trials by phase

Treatments under study

About Locally Advanced Pancreatic Ductal Adenocarcinoma Clinical Trials

Looking for clinical trials for Locally Advanced Pancreatic Ductal Adenocarcinoma? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Pancreatic Ductal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Early Phase 1

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+2 more
OHSU Knight Cancer Institute12 enrolled1 locationNCT07089940
Recruiting
Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Not Applicable

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
British Columbia Cancer Agency200 enrolled1 locationNCT06574620
Recruiting
Phase 1Phase 2

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center56 enrolled1 locationNCT05688215
Recruiting
Phase 2

PULSAR in Systemic Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaOligometastatic Pancreatic Ductal Adenocarcinoma
Samsung Medical Center47 enrolled1 locationNCT07269626
Recruiting

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
University of California, San Francisco70 enrolled1 locationNCT06600906
Recruiting
Not Applicable

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Fox Chase Cancer Center16 enrolled1 locationNCT06984562
Recruiting
Phase 1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04484909
Recruiting
Phase 2

A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Ductal Adenocarcinoma
West China Hospital23 enrolled1 locationNCT07101679
Recruiting
Phase 2

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Locally Advanced Pancreatic Ductal Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06472037